EYPT.NASDAQEyepoint Pharmaceuticals, INC

10-Q: EyePoint Pharmaceuticals Reports Q1 2025 Results, Driven by Royalty Income and DURAVYU Progress

Sentiment:

Quarterly Report

📋All filings for Eyepoint Pharmaceuticals, INC
🔒Login to Follow

EyePoint Pharmaceuticals' Q1 2025 results show increased revenue driven by royalty income, progress in DURAVYU clinical trials, and a net loss of $45.2 million.

Worse than expectedThe company's net loss increased from $29.3 million to $45.2 million year-over-year, indicating a worsening financial performance.

Summary

  • EyePoint Pharmaceuticals reported a net loss of $45.2 million for the three months ended March 31, 2025, compared to a net loss of $29.3 million for the same period in 2024.
  • Total revenue increased to $24.5 million from $11.7 million year-over-year, primarily driven by a significant increase in royalty income.
  • Royalty income increased by $12.2 million due to the recognition of deferred SWK royalty revenue, which was terminated in March 2025.
  • Research and development expenses increased to $58.6 million, up from $30.1 million in the prior year, due to increased clinical trial costs for DURAVYU.
  • The company's cash, cash equivalents, and investments in marketable securities totaled $318.2 million as of March 31, 2025.
  • EyePoint expects these funds to support operations into 2027.
  • Patient enrollment in the Phase 3 LUGANO and LUCIA trials for DURAVYU in wet AMD is exceeding expectations, with top-line data expected in the second half of 2026.
  • The company anticipates meeting with the FDA in Q2 2025 to finalize the pivotal program for DURAVYU in DME, with a potential start in 2026.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While revenue increased, the net loss also increased, and the company faces ongoing risks and uncertainties. The progress of DURAVYU is a positive sign, but regulatory and clinical trial risks remain.

Positives

  • Total revenues increased by 109% compared to the same period last year.
  • Patient enrollment in DURAVYU's Phase 3 trials is exceeding expectations.
  • The company believes its current cash position is sufficient to fund operations into 2027.
  • The Phase 2 VERONA clinical trial of DURAVYU in DME met both primary and secondary endpoints.
  • The company is on track to complete enrollment for both LUGANO and LUCIA in the second half of 2025.
  • The company extended the lease for its headquarters in Watertown, Massachusetts to May 31, 2028.

Negatives

  • The company reported a net loss of $45.2 million for the quarter, an increase from the $29.3 million loss in the same period last year.
  • Research and development expenses increased significantly, impacting profitability.
  • The company has a history of operating losses and has not had significant recurring cash inflows from revenue.
  • The company is subject to a DOJ investigation regarding sales, marketing, and promotional practices related to DEXYCU.

Risks

  • The company's ability to obtain regulatory approval for DURAVYU is uncertain.
  • Clinical trial outcomes may not be favorable.
  • The company may need to raise additional capital in the future, which may not be available on favorable terms.
  • The DOJ investigation could have a material impact on the company's financial condition.
  • The company is dependent on contract research organizations, vendors, and clinical investigators.
  • The company's ability to manufacture DURAVYU in sufficient quantities and quality is not guaranteed.
  • The company received a warning letter from the FDA in July 2024 pertaining to YUTIQ manufacturing.

Future Outlook

EyePoint expects its current cash resources to fund operations into 2027 and anticipates completing patient enrollment in the LUGANO and LUCIA clinical trials in the second half of 2025, with top-line data expected in the second half of 2026. The company also expects to meet with the FDA in Q2 2025 to finalize the pivotal program for DURAVYU in DME, with a potential start in 2026.

Management Comments

  • The company is focused on completing patient enrollment in the LUGANO and LUCIA clinical trials for DURAVYU in the second half of 2025 and reporting top-line data in the second half of 2026.
  • The company also expects to meet with the US FDA in the second quarter of 2025 to finalize the pivotal program for DURAVYU in DME with an expectation for that program to potentially begin in 2026.

Industry Context

EyePoint Pharmaceuticals is operating in the competitive ophthalmic market, focusing on retinal diseases. The progress of DURAVYU in wet AMD and DME positions the company to potentially compete with established anti-VEGF therapies. The company's Durasert E technology offers a sustained drug delivery approach, which could differentiate it from existing treatments requiring frequent injections.

Comparison to Industry Standards

  • Competitors in the wet AMD and DME space include companies like Regeneron (Eylea) and Roche/Novartis (Lucentis and Vabysmo).
  • These companies have established products with significant market share.
  • EyePoint's DURAVYU aims to provide a longer-lasting treatment option, potentially reducing the treatment burden for patients compared to the standard monthly or bi-monthly injections required by existing anti-VEGF therapies.
  • The rapid enrollment rates in the LUGANO and LUCIA trials suggest strong interest from investigators and patients, potentially indicating a perceived unmet need for longer-acting treatments.
  • The company's focus on a TIE-2 agonist (EYP-2301) also aligns with industry trends exploring alternative pathways to address retinal diseases.

Legal Proceedings

  • The company is subject to a DOJ investigation regarding sales, marketing, and promotional practices related to DEXYCU.

Related Party Transactions

  • Nancy S. Lurker, Vice Chair of the Board, is a member of the board of directors of Altasciences, with which the Company conducts business.
  • The company recorded $0.2 million and $0.6 million of research and development expense related to preclinical and analytical services provided by Altasciences for the three months ended March 31, 2025 and 2024, respectively.

Stakeholder Impact

  • Shareholders: The increased net loss may negatively impact shareholder value, but progress in DURAVYU clinical trials could provide future upside.
  • Employees: The company's ability to fund operations into 2027 provides job security, but potential future capital raises could impact employee equity.
  • Patients: Successful development and approval of DURAVYU could provide a new treatment option for wet AMD and DME.
  • Collaboration Partners: Continued collaboration with ANI, Betta, and Ocumension is important for revenue generation and market expansion.

Next Steps

  • Complete patient enrollment in the LUGANO and LUCIA clinical trials for DURAVYU in the second half of 2025.
  • Report top-line data from the LUGANO and LUCIA clinical trials in the second half of 2026.
  • Meet with the US FDA in the second quarter of 2025 to finalize the pivotal program for DURAVYU in DME.
  • Potentially begin the pivotal program for DURAVYU in DME in 2026.
  • Implement corrective and preventive actions required by the Warning Letter to the satisfaction of the FDA.

Key Dates

DateDescription
November 1, 2013Original Lease date between Original Landlord and Original Tenant.
March 28, 2018Date of warrant issuance to SWK to purchase 40,910 shares at $11.00 per share.
June 26, 2018Date of warrant issuance to SWK to purchase 7,773 shares at $19.30 per share.
November 2, 2018Date of Exclusive License Agreement with Ocumension Therapeutics.
August 1, 2019Start date of consecutive six-month offering periods for the Employee Stock Purchase Plan (ESPP).
August 2020EyePoint entered into an at-the-market facility (ATM Facility) with Cantor Fitzgerald & Co.
November 2021Issuance of 3,272,727 shares of Pre-Funded Warrants (PFW) to purchase common stock, in connection with the underwritten public offering.
May 2, 2022Date of exclusive license agreement with Betta Pharmaceuticals Co., Ltd.
August 2022EyePoint received a subpoena from the U.S. Attorneys Office for the District of Massachusetts.
May 17, 2023Date of Product Rights Agreement (PRA) with ANI (formerly Alimera).
June 20, 2023Approval date of the 2023 Long-Term Incentive Plan by stockholders.
January 2024SWK exercised their warrants in full via cashless exercise resulting in the net share issuance of 25,666 shares.
February 2024FDA inspection at the Company's Watertown facility.
April 18, 20242,181,818 PFWs were exercised in full as a cashless exercise, resulting in a net issuance of 2,180,776 shares of common stock.
July 2024The Company received a warning letter from the FDA pertaining to YUTIQ manufacturing.
September 30, 2024Effective date of the amendment to the Northbridge Lease.
December 31, 2024End of the fiscal year for the Annual Report on Form 10-K.
January 1, 2025No further royalty is due to SWK on net revenues beginning this date.
January 8, 2025Appointment of Reginald J. Sanders, M.D., FASRS to the Company's Board of Directors.
March 1, 2025The Company's obligation to pay base rent began on this date.
March 18, 2025ANI announced that it completed the buyout of its 3.125% perpetual royalty obligation to SWK.
March 31, 2025Date of the Fifth Amendment to Lease for the Watertown headquarters.
March 31, 2025End of the first quarter for the quarterly report on Form 10-Q.
May 2025Presentation of 24-week topline results from the Phase 2 VERONA study in DME at the Retina World Congress.
May 8, 2025Date of the filing of the quarterly report on Form 10-Q.
Second Quarter 2025Expected meeting with the US FDA to finalize the pivotal program for DURAVYU in DME.
Second Half 2025Expected completion of patient enrollment in the LUGANO and LUCIA clinical trials for DURAVYU in wet AMD.
Second Half 2026Expected reporting of top-line data from the LUGANO and LUCIA clinical trials.
2026Potential start of the pivotal program for DURAVYU in DME.

Keywords

DURAVYU, EyePoint Pharmaceuticals, Clinical Trials, Wet AMD, DME, Royalty Income, Financial Results, EYP-1901, Vorolanib, Retinal Diseases

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.